Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Irisity in conjunction with the acquisition of Agent Vi and a directed share issue
Mandate

Vinge advises Irisity in conjunction with the acquisition of Agent Vi and a directed share issue

September 03, 2021 M&A Capital Markets and Public M&A EU, Competition and Regulatory

Vinge has advised Irisity AB (publ) in connection with its acquisition of all shares in the Israeli company Agent Video Intelligence Ltd for a purchase price of approximately SEK 580 million.

The purchase price shall be paid in cash, and in part by way of newly issued shares in Irisity. Closing is subject to a resolution adopted at Irisity’s extraordinary general meeting to authorise the board of directors to adopt a resolution concerning a non-cash issue.

In connection with the closing of the transaction, Vinge advised Irisity regarding a directed share issue that was performed as an accelerated bookbuilding arranged by Erik Penser Bank at a subscription price of SEK 49. Irisity received SEK 130 million before issue costs.

Vinge’s team consisted of Anders Strid, Anna Ståhlklo (M&A), Edin Agic (ECM) and Adrian Filipovic (ECM). S. Horowitx&Co acted as legal counsel in Israel in connection with the acquisition.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025